Notes
2019 US dollars
gross domestic product
Reference
Rui M, et al. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model. Advances in Therapy : 9 Jul 2020. Available from: URL: http://doi.org/10.1007/s12325-020-01418-7
Rights and permissions
About this article
Cite this article
Cisplatin plus gemcitabine cost effective for metastatic BC in China. PharmacoEcon Outcomes News 858, 5 (2020). https://doi.org/10.1007/s40274-020-6978-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6978-z